# OnCo record nct07562581 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07562581/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07562581", "NCT07562581" ;
  schema:name "A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC"@en ;
  schema:description "A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07562581/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07562581> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-06-15" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/anlotinib/> ;
  onco:companies <https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/> .